版本:
中国

BRIEF-Galena Biopharma evaluates strategic alternatives

March 16 Galena Biopharma Inc

* Galena Biopharma reports fourth quarter and year end 2016 financial results and provides a corporate update

* Q4 loss per share $0.49

* Galena Biopharma - working closely with advisors to evaluate strategic alternatives, including monetizing assets, sale of co, a business combination Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐